Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Manidipine 6300. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.69 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.69 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.69 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Manidipine 6300 SCHEMBL247919 | 1.00 | ADRA1A (0.71) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL137616 | 1.00 | ADRA1A (0.71) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL137617 | 1.00 | ADRA1A (0.71) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL6275097 | 1.00 | ADRA1A (0.71) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL1491187 | 0.99 | ADRA1A (0.70) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL1491189 | 0.99 | ADRA1A (0.70) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL28927600 | 0.99 | ADRA1A (0.70) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL247471 | 0.99 | MAPT (0.70) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL29801590 | 0.99 | MAPT (0.70) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL49368 | 0.99 | MAPT (0.70) | ADRA1AMAPTTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057819-A1 | DRUG COMBINATIONS FOR INHIBITING CORONAVIRUS REPLICATION | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2025-02-20 | — | — | US | claimed |
| WO-2023115220-A1 | DRUG COMBINATIONS FOR INHIBITING CORONAVIRUS REPLICATION | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2023-06-29 | — | — | WO | claimed |
| US-9018376-B2 | Polymorphic forms of manidipine | CIPLA LIMITED (IN) | 2015-04-28 | — | — | US | claimed |
| US-20120232091-A1 | Polymorphic Forms of Manidipine | CIPLA LIMITED (IN) | 2012-09-13 | — | — | US | claimed |
| EP-2470505-A2 | POLYMORPHIC FORMS OF MANIDIPINE | Cilpa Limited (IN) | 2012-07-04 | — | — | EP | claimed |
| CN-1813699-B | pharmaceutical composition | OTSUKA PHARMA CO LTD | 2012-04-18 | — | — | CN | claimed |
| WO-2011023954-A2 | POLYMORPHIC FORMS OF MANIDIPINE | CIPLA LIMITED (IN) | 2011-03-03 | — | — | WO | claimed |
| CN-100350977-C | Pharmaceutical composition | OTSUKA PHARMA CO LTD (JP) | 2007-11-28 | — | — | CN | claimed |
| CN-1813699-A | Medicinal composition | OTSUKA PHARMA CO LTD (JP) | 2006-08-09 | — | — | CN | claimed |
| CN-1518461-A | Pharmaceutical composition | 大V制药株式会社 | 2004-08-04 | — | — | CN | claimed |
| EP-4714447-A1 | DRUG COMBINATIONS OF BCL-XL INHIBITORS FOR TREATMENT OF CANCER | Stichting Amsterdam UMC (NL) | 2026-03-25 | — | — | EP | disclosed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| CN-120091810-A | Methods and highly bioavailable permeable compounds for treating viral diseases | 基里尔·迪丹克 | 2025-06-03 | — | — | CN | disclosed |
| CN-100350977-C | Pharmaceutical composition | OTSUKA PHARMA CO LTD (JP) | 2007-11-28 | — | — | CN | disclosed |
| CN-1856328-A | Composition for intraorally rapidly disintegrating tablet | FUJI CHEM IND CO LTD (JP) | 2006-11-01 | — | — | CN | disclosed |
| CN-1813699-A | Medicinal composition | OTSUKA PHARMA CO LTD (JP) | 2006-08-09 | — | — | CN | disclosed |
| CN-1732935-A | Compound orally administered formulation of Carvedilol and manidipine | HU CAIZHONG (CN) | 2006-02-15 | — | — | CN | disclosed |
| CN-1518461-A | Pharmaceutical composition | 大V制药株式会社 | 2004-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | CACNA1C 2414/4885ADRA1A 1859/4885MAPT 832/4885 |
| US-20120232091-A1 | Polymorphic Forms of Manidipine | SLC6A3, SLC6A4, ADH5 | CACNA1C 128/4885ADRA1A 114/4885MAPT 250/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | CACNA1C 4629/4885ADRA1A 3821/4885MAPT 330/4885 |
| US-20250057819-A1 | DRUG COMBINATIONS FOR INHIBITING CORONAVIRUS REPLICATION | MME, ACE, ACE2 | CACNA1C 939/4885ADRA1A 1891/4885MAPT 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.